Detalles de la búsqueda
1.
Preoperative Treatment of Locally Advanced Rectal Cancer.
N Engl J Med
; 389(4): 322-334, 2023 Jul 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37272534
2.
Current Practices in Hepatic Artery Infusion (HAI) Chemotherapy: An International Survey of the HAI Consortium Research Network.
Ann Surg Oncol
; 30(12): 7362-7370, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37702903
3.
Impact of new cancer therapies on outpatient treatment delivery for colorectal cancer: A population-based study.
Int J Health Plann Manage
; 37(1): 258-270, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34545610
4.
The Impact of Chronic Kidney Disease in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation.
Dis Colon Rectum
; 64(12): 1471-1478, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34657078
5.
A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer.
Invest New Drugs
; 38(4): 1077-1084, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31506897
6.
Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
J Surg Oncol
; 121(3): 480-485, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31853990
7.
Outcomes of Surgical and Chemotherapeutic Treatments of Goblet Cell Carcinoid Tumors of the Appendix.
Ann Surg Oncol
; 25(8): 2391-2399, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29916007
8.
ASO Visual Abstract: Current Practices in Hepatic Artery Infusion (HAI) Chemotherapy-An International Survey of the HAI Consortium Research Network.
Ann Surg Oncol
; 30(13): 8021-8022, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37770725
9.
A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Invest New Drugs
; 36(4): 674-682, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29725881
10.
Prognostic Factors for Locoregional Recurrence in Neuroendocrine Tumors of the Rectum.
Dis Colon Rectum
; 61(2): 187-192, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29337773
11.
The utility of abbreviated patient-reported outcomes for predicting survival in early stage colorectal cancer.
Cancer
; 123(10): 1839-1847, 2017 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28081292
12.
Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Support Care Cancer
; 24(2): 799-805, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26184500
13.
Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
Cancer
; 121(4): 527-34, 2015 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25332117
14.
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).
Cancer
; 121(13): 2193-7, 2015 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25827820
15.
Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group.
Ann Surg Oncol
; 22(8): 2685-99, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25366583
16.
Effect of M1a and M1b category in metastatic colorectal cancer.
Oncologist
; 19(7): 720-6, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24899642
17.
Association between palliative resection of the primary tumor and overall survival in a population-based cohort of metastatic colorectal cancer patients.
Ann Surg Oncol
; 21(12): 3917-23, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24859937
18.
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
Lancet Oncol
; 14(3): 228-35, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23414585
19.
Establishing a robust radioligand therapy program: A practical approach for North American centers.
Cancer Med
; 13(3): e6780, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38214130
20.
Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 trial.
Clin Cancer Res
; 2024 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38727700